DFP 11207

Drug Profile

DFP 11207

Alternative Names: DFP-11207

Latest Information Update: 09 Dec 2015

Price : $50

At a glance

  • Originator Delta-Fly Pharma
  • Class Antineoplastics; Small interfering RNA; Small molecules
  • Mechanism of Action RNA interference; Thymidylate synthase expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 09 Dec 2015 Phase-II development for Solid tumours (Late-stage disease) is ongoing in USA (NCT02171221)
  • 01 Jun 2014 Phase-I clinical trials in Solid tumours (second-line or greater therapy) in USA (PO) (NCT02171221)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top